Company profile
Inhibitor Therapeutics, Inc.
OTC: INTI · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
29DFH 17DQ 43GM —SS 44
v0.1 · 55/100 weight · provisional
↑ listing tenure, market scale · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.3M
Employees
8
as of 2026-08-22
Market cap
$15.4M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02021
Net income-$3.3M-$3.3M2025
Operating income-$3.4M-$3.4M2025
Total assets$2.5M$2.5M2025
Liabilities$3.8M$3.8M2025
Equity-$1.3M-$1.3M2025
Revenue trend
FY2014 – FY2021 · USD
FY14
FY15
FY16
FY17
FY18
FY20
FY20
FY21
Revenue by segment
Filed disclosures · FY2025
By product
Royalty100%
By geography
Not disclosed.
The read
What is Inhibitor Therapeutics, Inc.’s revenue?
Inhibitor Therapeutics, Inc. booked $0 in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
KALA BIO, Inc.30DTvardi Therapeutics, Inc.35DPalatin Technologies, Inc.40DBiomind Labs Inc.——BioCardia, Inc.29DAdagio Medical Holdings, Inc.24DNeighbors
Hillsborough →Key facts
CEOFrancis E. O'Donnell Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersTampa, FL
ExchangeOTC: INTI
Employees8
IPO date2013-09-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.